Page last updated: 2024-09-04

olmesartan and clozapine

olmesartan has been researched along with clozapine in 5 studies

Compound Research Comparison

Studies
(olmesartan)
Trials
(olmesartan)
Recent Studies (post-2010)
(olmesartan)
Studies
(clozapine)
Trials
(clozapine)
Recent Studies (post-2010) (clozapine)
8411855549,6917473,148

Protein Interaction Comparison

ProteinTaxonomyolmesartan (IC50)clozapine (IC50)
Adenylate cyclase type 1 Rattus norvegicus (Norway rat)0.14
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)3.6
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.032
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)1.47
Muscarinic acetylcholine receptor M2Homo sapiens (human)0.476
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.045
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.1233
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)0.1534
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)0.1534
5-hydroxytryptamine receptor 1AHomo sapiens (human)0.15
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)0.031
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)0.1534
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.013
Alpha-2A adrenergic receptorHomo sapiens (human)0.09
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)0.14
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)0.1534
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.0096
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)2
D(2) dopamine receptorHomo sapiens (human)0.2044
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.0886
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)0.0567
Alpha-2B adrenergic receptorHomo sapiens (human)0.023
Alpha-2C adrenergic receptorHomo sapiens (human)0.0079
DRattus norvegicus (Norway rat)1.066
D(3) dopamine receptorRattus norvegicus (Norway rat)0.9312
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)1.2695
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)3.5772
D(2) dopamine receptorBos taurus (cattle)1.804
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.078
D(1A) dopamine receptorHomo sapiens (human)0.107
D(4) dopamine receptorHomo sapiens (human)0.0796
Adenylate cyclase type 3Rattus norvegicus (Norway rat)0.14
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)3.5772
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)3.5772
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)0.0567
Sodium-dependent noradrenaline transporter Homo sapiens (human)1.47
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)5.7544
Histamine H2 receptorHomo sapiens (human)3.61
Alpha-1D adrenergic receptorHomo sapiens (human)0.035
D(1B) dopamine receptorRattus norvegicus (Norway rat)0.9312
Adenylate cyclase type 2Rattus norvegicus (Norway rat)0.14
Adenylate cyclase type 4Rattus norvegicus (Norway rat)0.14
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.0658
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.0658
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)0.373
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)0.587
D(4) dopamine receptorRattus norvegicus (Norway rat)0.9312
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)0.587
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.0338
Histamine H1 receptorRattus norvegicus (Norway rat)0.023
Sodium-dependent serotonin transporterHomo sapiens (human)0.546
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)0.028
5-hydroxytryptamine receptor 2AMus musculus (house mouse)0.028
Histamine H1 receptorHomo sapiens (human)0.0049
D(3) dopamine receptorHomo sapiens (human)0.354
Adenylate cyclase type 8Rattus norvegicus (Norway rat)0.14
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.081
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)0.0567
5-hydroxytryptamine receptor 6Homo sapiens (human)0.0171
D(2) dopamine receptorMus musculus (house mouse)0.29
D(2) dopamine receptorRattus norvegicus (Norway rat)0.6759
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)3.6
5-hydroxytryptamine receptor 2BMus musculus (house mouse)0.028
Adenylate cyclase type 6Rattus norvegicus (Norway rat)0.14
Adenylate cyclase type 5Rattus norvegicus (Norway rat)0.14
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)1.4162
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)3.6
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)3.6
5-hydroxytryptamine receptor 1AMus musculus (house mouse)2
Adenylyl cyclase 7 Rattus norvegicus (Norway rat)0.14
DBos taurus (cattle)4.09

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Ekins, S; Williams, AJ; Xu, JJ1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1

Other Studies

5 other study(ies) available for olmesartan and clozapine

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Glutathione; Pharmacology; Sulfur Radioisotopes

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013